Literature DB >> 10382939

Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas.

P Kanavaros1, K Stefanaki, K Valassiadou, J Vlachonikolis, M Mavromanolakis, M Vlychou, S Kakolyris, V Gorgoulis, M Tzardi, V Georgoulias.   

Abstract

This study investigated the combined immunoexpression of p53, p21, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas and correlated expression patterns with tumour stage and grade. Paraffin sections from 98 cases of colorectal adenocarcinomas were stained by immunohistochemistry for p53, p21, bcl-2, bax, Rb and MIB-1 (Ki67) proteins. In addition, 12 cases of colorectal adenomas and normal colorectal mucosa were studied in parallel. P53, p21, bcl-2, bax, Rb and Ki67 proteins were detected in at least 5% of tumour cells in 63/98, 72/98, 52/98, 96/98 and 98/98 adenocarcinomas, respectively. Comparative study of the normal-adenoma-carcinoma tissues revealed abrogation of the normal immunotopography in adenomas and adenocarcinomas, and considerable modifications, increase or reduction, of the expression of p53, p21, bcl-2, bax, Rb and Ki67 proteins in adenocarcinomas when compared with normal mucosa and adenomas. Statistically significant correlations were found between low bax expression and Dukes C stage of carcinomas, Ki67 expression and carcinoma grade, and Ki67 and Rb expression. P53, p21, bcl-2 and Rb immunoexpression did not correlate with tumour stage or grade. Our findings show that low bax immunoexpression is frequently related to colorectal adenocarcinomas with lymph node metastases suggesting that low levels of bax expression play a role in late stage colorectal cancer. The correlation between Ki67 and Rb expression, in view of previous data that the hyperphosphorylated inactive Rb protein is frequently increased in colorectal adenocarcinomas, suggests that Rb protein is somewhat ineffective in inhibiting the cell-cycle progression in these malignancies. Furthermore, our findings provide immunohistochemical evidence that the abrogation of the normal immunotopography and the modifications of the expression of p53, p21, bcl-2, bax, Rb and Ki67 proteins reflect important events in colorectal oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382939     DOI: 10.1007/bf02787355

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  51 in total

1.  Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia.

Authors:  L Kaklamanis; A Savage; N Mortensen; P Tsiotos; I Doussis-Anagnostopoulou; S Biddolph; R Whitehouse; A L Harris; K C Gatter
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

2.  Inhibition of Bax channel-forming activity by Bcl-2.

Authors:  B Antonsson; F Conti; A Ciavatta; S Montessuit; S Lewis; I Martinou; L Bernasconi; A Bernard; J J Mermod; G Mazzei; K Maundrell; F Gambale; R Sadoul; J C Martinou
Journal:  Science       Date:  1997-07-18       Impact factor: 47.728

3.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.

Authors:  M Krajewska; S Krajewski; J I Epstein; A Shabaik; J Sauvageot; K Song; S Kitada; J C Reed
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.

Authors:  N Rampino; H Yamamoto; Y Ionov; Y Li; H Sawai; J C Reed; M Perucho
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

6.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.

Authors:  S Krajewski; M Krajewska; A Shabaik; T Miyashita; H G Wang; J C Reed
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

7.  Induction of p21 (WAF-1/CIP1) during differentiation.

Authors:  R A Steinman; B Hoffman; A Iro; C Guillouf; D A Liebermann; M E el-Houseini
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

8.  Expression of the retinoblastoma protein is regulated in normal human tissues.

Authors:  C Cordon-Cardo; V M Richon
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

9.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.

Authors:  T Miyashita; J C Reed
Journal:  Blood       Date:  1993-01-01       Impact factor: 22.113

10.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.

Authors:  J W Harbour; S L Lai; J Whang-Peng; A F Gazdar; J D Minna; F J Kaye
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

View more
  4 in total

1.  Multiple biomarkers of colorectal tumor in a differential diagnosis model: a quantitative study.

Authors:  Wen Jin; Mei-Qin Gao; Zhi-Wu Lin; Dai-Xing Yang
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  ARHGAP24 regulates cell ability and apoptosis of colorectal cancer cells via the regulation of P53.

Authors:  Suiliang Zhang; Liang Sui; Juhua Zhuang; Saifei He; Yanan Song; Ying Ye; Wei Xia
Journal:  Oncol Lett       Date:  2018-07-04       Impact factor: 2.967

3.  Replacement of Nitrite in Meat Products by Natural Bioactive Compounds Results in Reduced Exposure to N-Nitroso Compounds: The PHYTOME Project.

Authors:  Simone G van Breda; Karen Mathijs; Harm-Jan Pieters; Virág Sági-Kiss; Gunter G Kuhnle; Panagiotis Georgiadis; Giovanna Saccani; Giovanni Parolari; Roberta Virgili; Rashmi Sinha; Gert Hemke; Yung Hung; Wim Verbeke; Ad A Masclee; Carla B Vleugels-Simon; Adriaan A van Bodegraven; Theo M de Kok
Journal:  Mol Nutr Food Res       Date:  2021-08-27       Impact factor: 6.575

4.  TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.

Authors:  Kathy L McGraw; Thomas Cluzeau; David A Sallman; Ashley A Basiorka; Brittany A Irvine; Ling Zhang; P K Epling-Burnette; Dana E Rollison; Mar Mallo; Lubomir Sokol; Francesc Solé; Jaroslaw Maciejewski; Alan F List
Journal:  Oncotarget       Date:  2015-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.